Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction

P. R. Maroko, L. D. Hillis, J. E. Muller, L. Tavazzi, G. R. Heyndrickx, M. Ray, M. Chiariello, A. Distante, J. Askenazi, J. Salerno, J. Carpentier, N. I. Reshetnaya, P. Radvany, P. Libby, D. S. Raabe, E. I. Chazov, P. Bobba, E. Braunwald

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

To evaluate hyaluronidase's effect in reducing post-infarction myocardial necrosis the authors randomized 91 patients with anterior infarction to control (45) or to hyaluronidase treatment (46) groups. A 35-lead precordial electrocardiogram was recorded on admission and seven days later. Hyaluronidase was administered intravenously after the first electrocardiogram and every six hours for 48 hours. QRS-complex changes were analyzed to assess the drug's effect. Precordial sites with ST-segment elevation (≥0.15 mV) on the initial electrocardiogram that retained an R wave were considered vulnerable for the development of electrocardiographic signs of necrosis. The sum of R-wave voltages of vulnerable sites fell more in the control group than in the hyaluronidase group (70.9±3.6% [±1 S.E.M.] vs. 54.2 ± 5.0% P< 0.01). Q waves appeared in 59.3 ± 4.9% of the vulnerable sites in control versus 46.4±4.9% in hyaluronidase-treated patients (P<0.05). Thus, hyaluronidase reduced the frequency of electrocardiographic signs of myocardial necrosis.

Original languageEnglish (US)
Pages (from-to)898-903
Number of pages6
JournalNew England Journal of Medicine
Volume296
Issue number16
StatePublished - 1977
Externally publishedYes

Fingerprint

Hyaluronoglucosaminidase
Necrosis
Myocardial Infarction
Electrocardiography
Infarction
Control Groups
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Maroko, P. R., Hillis, L. D., Muller, J. E., Tavazzi, L., Heyndrickx, G. R., Ray, M., ... Braunwald, E. (1977). Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction. New England Journal of Medicine, 296(16), 898-903.

Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction. / Maroko, P. R.; Hillis, L. D.; Muller, J. E.; Tavazzi, L.; Heyndrickx, G. R.; Ray, M.; Chiariello, M.; Distante, A.; Askenazi, J.; Salerno, J.; Carpentier, J.; Reshetnaya, N. I.; Radvany, P.; Libby, P.; Raabe, D. S.; Chazov, E. I.; Bobba, P.; Braunwald, E.

In: New England Journal of Medicine, Vol. 296, No. 16, 1977, p. 898-903.

Research output: Contribution to journalArticle

Maroko, PR, Hillis, LD, Muller, JE, Tavazzi, L, Heyndrickx, GR, Ray, M, Chiariello, M, Distante, A, Askenazi, J, Salerno, J, Carpentier, J, Reshetnaya, NI, Radvany, P, Libby, P, Raabe, DS, Chazov, EI, Bobba, P & Braunwald, E 1977, 'Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction', New England Journal of Medicine, vol. 296, no. 16, pp. 898-903.
Maroko, P. R. ; Hillis, L. D. ; Muller, J. E. ; Tavazzi, L. ; Heyndrickx, G. R. ; Ray, M. ; Chiariello, M. ; Distante, A. ; Askenazi, J. ; Salerno, J. ; Carpentier, J. ; Reshetnaya, N. I. ; Radvany, P. ; Libby, P. ; Raabe, D. S. ; Chazov, E. I. ; Bobba, P. ; Braunwald, E. / Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction. In: New England Journal of Medicine. 1977 ; Vol. 296, No. 16. pp. 898-903.
@article{c03c8e8cd35c4da1b2d5c533b5273ed5,
title = "Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction",
abstract = "To evaluate hyaluronidase's effect in reducing post-infarction myocardial necrosis the authors randomized 91 patients with anterior infarction to control (45) or to hyaluronidase treatment (46) groups. A 35-lead precordial electrocardiogram was recorded on admission and seven days later. Hyaluronidase was administered intravenously after the first electrocardiogram and every six hours for 48 hours. QRS-complex changes were analyzed to assess the drug's effect. Precordial sites with ST-segment elevation (≥0.15 mV) on the initial electrocardiogram that retained an R wave were considered vulnerable for the development of electrocardiographic signs of necrosis. The sum of R-wave voltages of vulnerable sites fell more in the control group than in the hyaluronidase group (70.9±3.6{\%} [±1 S.E.M.] vs. 54.2 ± 5.0{\%} P< 0.01). Q waves appeared in 59.3 ± 4.9{\%} of the vulnerable sites in control versus 46.4±4.9{\%} in hyaluronidase-treated patients (P<0.05). Thus, hyaluronidase reduced the frequency of electrocardiographic signs of myocardial necrosis.",
author = "Maroko, {P. R.} and Hillis, {L. D.} and Muller, {J. E.} and L. Tavazzi and Heyndrickx, {G. R.} and M. Ray and M. Chiariello and A. Distante and J. Askenazi and J. Salerno and J. Carpentier and Reshetnaya, {N. I.} and P. Radvany and P. Libby and Raabe, {D. S.} and Chazov, {E. I.} and P. Bobba and E. Braunwald",
year = "1977",
language = "English (US)",
volume = "296",
pages = "898--903",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "16",

}

TY - JOUR

T1 - Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction

AU - Maroko, P. R.

AU - Hillis, L. D.

AU - Muller, J. E.

AU - Tavazzi, L.

AU - Heyndrickx, G. R.

AU - Ray, M.

AU - Chiariello, M.

AU - Distante, A.

AU - Askenazi, J.

AU - Salerno, J.

AU - Carpentier, J.

AU - Reshetnaya, N. I.

AU - Radvany, P.

AU - Libby, P.

AU - Raabe, D. S.

AU - Chazov, E. I.

AU - Bobba, P.

AU - Braunwald, E.

PY - 1977

Y1 - 1977

N2 - To evaluate hyaluronidase's effect in reducing post-infarction myocardial necrosis the authors randomized 91 patients with anterior infarction to control (45) or to hyaluronidase treatment (46) groups. A 35-lead precordial electrocardiogram was recorded on admission and seven days later. Hyaluronidase was administered intravenously after the first electrocardiogram and every six hours for 48 hours. QRS-complex changes were analyzed to assess the drug's effect. Precordial sites with ST-segment elevation (≥0.15 mV) on the initial electrocardiogram that retained an R wave were considered vulnerable for the development of electrocardiographic signs of necrosis. The sum of R-wave voltages of vulnerable sites fell more in the control group than in the hyaluronidase group (70.9±3.6% [±1 S.E.M.] vs. 54.2 ± 5.0% P< 0.01). Q waves appeared in 59.3 ± 4.9% of the vulnerable sites in control versus 46.4±4.9% in hyaluronidase-treated patients (P<0.05). Thus, hyaluronidase reduced the frequency of electrocardiographic signs of myocardial necrosis.

AB - To evaluate hyaluronidase's effect in reducing post-infarction myocardial necrosis the authors randomized 91 patients with anterior infarction to control (45) or to hyaluronidase treatment (46) groups. A 35-lead precordial electrocardiogram was recorded on admission and seven days later. Hyaluronidase was administered intravenously after the first electrocardiogram and every six hours for 48 hours. QRS-complex changes were analyzed to assess the drug's effect. Precordial sites with ST-segment elevation (≥0.15 mV) on the initial electrocardiogram that retained an R wave were considered vulnerable for the development of electrocardiographic signs of necrosis. The sum of R-wave voltages of vulnerable sites fell more in the control group than in the hyaluronidase group (70.9±3.6% [±1 S.E.M.] vs. 54.2 ± 5.0% P< 0.01). Q waves appeared in 59.3 ± 4.9% of the vulnerable sites in control versus 46.4±4.9% in hyaluronidase-treated patients (P<0.05). Thus, hyaluronidase reduced the frequency of electrocardiographic signs of myocardial necrosis.

UR - http://www.scopus.com/inward/record.url?scp=0017328756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017328756&partnerID=8YFLogxK

M3 - Article

C2 - 846510

AN - SCOPUS:0017328756

VL - 296

SP - 898

EP - 903

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 16

ER -